William Blair Starts aTyr Pharma (LIFE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Citi Starts aTyr Pharma (LIFE) at Buy
June 1, 2015 8:04 AM EDTCiti initiated coverage on aTyr Pharma (NASDAQ: LIFE) with a Buy rating and a price target of $32.00.
For an analyst ratings summary and ratings history on aTyr Pharma click here. For more ratings news on aTyr Pharma click here.
Shares of aTyr Pharma closed at $22.89 yesterday.
... MoreJPMorgan Starts aTyr Pharma (LIFE) at Overweight
June 1, 2015 6:57 AM EDTJPMorgan initiated coverage on aTyr Pharma (NASDAQ: LIFE) with an Overweight rating and a price target of $42.00.
For an analyst ratings summary and ratings history on Life Technologies click here. For more ratings news on Life Technologies click here.
Shares of Life Technologies closed at $22.89 yesterday.
... MoreUPDATE: BMO Capital Starts aTyr Pharma (LIFE) at Outperform
June 1, 2015 6:34 AM EDT(Updated - June 1, 2015 7:03 AM EDT)
BMO Capital initiates coverage on aTyr Pharma (NASDAQ: LIFE) with a Outperform rating and a price target of $42.00.
Analyst Jim Birchenough commented, "Our favorable rating and outlook is supported by the company's identification of, and proprietary dominance in, the area of Physiocrine... More
